T32: Predoctoral and Postdoctoral Training Program in Nanotechnology for Cancer Research

项目摘要 纳米技术和医学之间的接口是科学探索和 创造新的和改进的诊断和治疗工具，以检测、治疗、治愈和预防 人类疾病。我们建议创建一个博士后和博士后综合培训计划 在用于癌症研究的纳米技术(NTCR)中，定位于这个界面。它基于两个父代 同一地区的R25和T32培训补助金。该计划将建立一个独特的国家资源， 癌症生物学、工业基础研究中的跨学科和协同计划 癌症医学方面的合作和转化研究。该项目培养博士后和 经过跨学科培训的博士后研究员，为实现以下目标的技术奠定基础 对癌细胞功能的内部观察，而不是目前有限的黑匣子输入输出技术 使用，引入新的分子成像方法，开发新的高通量诊断工具，以及 设计治疗人类癌症的新型药物/抗体/siRNA病毒和非病毒递送系统。NTCR 研究人员开发新的癌症诊断方法来评估每个患者的预后和最佳 根据患者的遗传和表观遗传标记以及疾病表型和 为每个患者选择和优化的治疗方法。NTCR学员参加三门课程中的一门 根据他们的背景而定的核心课程，以及癌症纳米生物技术实验室课程。他们 参加期刊俱乐部和专门的年度研讨会，以及临床会议和肿瘤 冲浪板。NTCR项目将每年招募拥有医学博士学位和/或博士学位的优秀学员 以及生物化学、物理、分子/细胞/癌症生物学或 工程/物理学科，稳定人数为2名博士后和6名博士后研究员。这个 NTCR项目为期3年，博士后实习生为期4-5年。NTCR 研究员利用NCI指定的Sidney Kimmel的研究和临床资源 综合癌症中心，路德维克癌症遗传和治疗中心，索尔 高曼胰腺癌中心，体内细胞和分子成像中心，以及 最近成立的约翰·霍普金斯大学独特的教育资源和实验设施 纳米生物技术研究所(INBT)，以前是癌症纳米技术中心的所在地 卓越(CCNE)，目前是物理科学-肿瘤学中心(PSOC)。

Project Summary The interface between nanotechnology and medicine is a new frontier for scientific exploration and for the creation of new and improved diagnostic and therapeutic tools to detect, treat, cure, and prevent human diseases. We propose to create an integrated predoctoral and postdoctoral training program in nanotechnology for cancer research (NTCR) that is positioned at this interface. It is based on two parent R25 and T32 training grants in the same area. This program will establish a unique national resource with interdisciplinary and synergistic programs in fundamental research in cancer biology, industrial collaboration, and translational research in cancer medicine. This program fosters predoctoral and postdoctoral fellows who are trained across disciplines to lay foundations for technologies that enable an inside-view of cancer cell functions as opposed to the limited black-box input-output techniques currently used, introduce new modalities for molecular imaging, develop new high-throughput diagnostic tools, and engineer novel drug/antibody/siRNA viral and non-viral delivery systems to treat human cancers. NTCR fellows develop novel cancer diagnostics to evaluate each individual patient's prognosis and optimal treatment, based upon the patients' genetic and epigenetic markers and disease phenotype and therapeutics that are selected and optimized for each individual patient. NTCR trainees take one of three core courses depending on their background, as well as a lab course in cancer nanobiotechnology. They participate in a journal club and a dedicated annual symposium, as well as clinical conferences and tumor boards. The NTCR program will recruit outstanding trainees every year with MD and/or PhD degrees and diverse backgrounds in either biochemistry, physics, molecular/cellular/cancer biology, or an engineering/physics discipline for a steady state number of 2 postdoctoral and 6 predoctoral fellows. The NTCR program lasts 3 years for postdoctoral trainees and 4-5 years for predoctoral trainees. NTCR fellows take advantage of research and clinical resources at the NCI-designated Sidney Kimmel Comprehensive Cancer Center, the Ludwick Center for Cancer Genetics and Therapeutics, The Sol Goldman Pancreatic Cancer Center, and the In Vivo Cellular and Molecular Imaging Center, as well as the unique educational resources and experimental facilities of the recently established Johns Hopkins Institute for NanoBioTechnology (INBT), which previously housed the center for cancer nanotechnology excellence (CCNE) and currently the physical sciences-oncology center (PSOC).